Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
06 Jul 2022
06 Jul 2022
Historique:
received:
19
03
2022
accepted:
22
06
2022
entrez:
6
7
2022
pubmed:
7
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
SARS-CoV-2 vaccines BNT162b2, mRNA-1273, and Ad26.COV2.S received emergency use authorization by the U.S. Food and Drug Administration in 2020/2021. Individuals being vaccinated were invited to participate in a prospective longitudinal comparative study of immune responses elicited by the three vaccines. In this observational cohort study, immune responses were evaluated using a SARS-CoV-2 spike protein receptor-binding domain ELISA, SARS-CoV-2 virus neutralization assays and an IFN- γ ELISPOT assay at various times over six months following initial vaccination. mRNA-based vaccines elicited higher magnitude humoral responses than Ad26.COV2.S; mRNA-1273 elicited the most durable humoral response, and all humoral responses waned over time. Neutralizing antibodies against the Delta variant were of lower magnitude than the wild-type strain for all three vaccines. mRNA-1273 initially elicited the greatest magnitude of T cell response, but this declined by 6 months. Declining immunity over time supports the use of booster dosing, especially in the setting of emerging variants.
Identifiants
pubmed: 35794181
doi: 10.1038/s41541-022-00504-x
pii: 10.1038/s41541-022-00504-x
pmc: PMC9258461
doi:
Types de publication
Journal Article
Langues
eng
Pagination
77Subventions
Organisme : Burroughs Wellcome Fund (BWF)
ID : 1013362.02
Informations de copyright
© 2022. The Author(s).
Références
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
Nat Med. 2022 May;28(5):1063-1071
pubmed: 35189624
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
JAMA. 2021 Apr 20;325(15):1535-1544
pubmed: 33704352
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Nov 4;385(19):1774-1785
pubmed: 34551225
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594
Nature. 2021 Aug;596(7871):268-272
pubmed: 34107529
EClinicalMedicine. 2022 Mar 05;45:101326
pubmed: 35261970
Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
N Engl J Med. 2021 Sep 2;385(10):951-953
pubmed: 34260834
Pathogens. 2021 Jun 06;10(6):
pubmed: 34204122
Front Immunol. 2020 Mar 31;11:513
pubmed: 32296430
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Front Public Health. 2022 Mar 31;10:847384
pubmed: 35433614
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343
pubmed: 34555004
Cell. 2022 Jul 7;185(14):2434-2451.e17
pubmed: 35764089
BMC Infect Dis. 2022 Mar 20;22(1):270
pubmed: 35307024
mBio. 2021 Jun 29;12(3):e0069621
pubmed: 34060334
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Science. 2021 Mar 25;:
pubmed: 33766944
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279